source
- Former FDA commissioner sees hope for stability under new acting leader Kyle DiamantasAt a recent STAT Breakthrough Summit West, former FDA commissioner David Kessler addressed concerns about the agency’s recent turmoil and staff departures. Kessler said the appointment of acting c…
- BioMarin's BMN-401 fails key endpoint in ENPP1 deficiency Phase 3 trialAn experimental therapy, BMN 401, was tested in a Phase 3 study for ENPP1 deficiency, a rare disease. The drug missed one of its two co-primary endpoints, a result that regulators consider critical…